This innovation saved lives in the pandemic. Now it’s showing strength against cancer.

The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, according to the drugs’ sponsors.

View original article
Contributor: Daniel Gilbert